Primary Myelofibrosis: all 431 studies
Page 1 of 5. Open to participants first (118), then studies with results posted, then the rest; newest registration first within each.
- An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell TransplantationNot yet recruitingNCT07883382Phase 1/2
- Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative NeoplasmsNot yet recruitingNCT07872709Phase 2
- MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative NeoplasmsRecruitingNCT07863466
- Special Stains in Assessment of Bone Marrow FibrosisNot yet recruitingNCT07853417
- A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsRecruitingNCT07849231Phase 1
- Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor TypeNot yet recruitingNCT07805746
- Pacritinib Effectiveness in Real-world SettingsRecruitingNCT07774455
- Flonoltinib Maleate Oral Regimens in Patients With MyelofibrosisNot yet recruitingNCT07750574Phase 2
- Revumenib in Patients With MyelofibrosisNot yet recruitingNCT07734077Phase 1/2
- A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking RuxolitinibRecruitingNCT07623161Phase 3
- Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative NeoplasmRecruitingNCT07590986
- A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk MyelofibrosisRecruitingNCT07551427Phase 2
- Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe MyelofibrosisNot yet recruitingNCT07539779Phase 2/3
- Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood CancersNot yet recruitingNCT07529951Phase 1
- Safety and Tolerability of ZE74-0282 in Healthy VolunteersRecruitingNCT07527221Phase 1
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingNCT07521046Phase 1
- ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid LeukemiaNot yet recruitingNCT07518940Not applicable
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingNCT07498205Phase 4
- To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment SubjectsRecruitingNCT07480824Phase 1
- Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary MyelofibrosisNot yet recruitingNCT07471503Phase 2
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsRecruitingNCT07469891Phase 1
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNot yet recruitingNCT07447817Phase 2
- Study of INCA036978 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07441694Phase 1
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With MyelofibrosisNot yet recruitingNCT07440654Not applicable
- Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With MyelofibrosisNot yet recruitingNCT07424950Phase 2
- A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of ConceptRecruitingNCT07419178Not applicable
- Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have ThrombocytopeniaRecruitingNCT07394153Phase 2
- Therapeutic RSK1 Targeting in Myeloid MalignanciesRecruitingNCT07379125Phase 1
- MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)RecruitingNCT07362225
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)RecruitingNCT07357727Phase 3
- WELL-MPN: A Digital Lifestyle App for Patients With MPNsNot yet recruitingNCT07349134Not applicable
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTRecruitingNCT07302776Phase 1
- Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone MarrowRecruitingNCT07281781Phase 1/2
- A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk MyelofibrosisRecruitingNCT07250646Phase 1
- Momelotinib Effectiveness in MyelofibrosisNot yet recruitingNCT07249606
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingNCT07228624Phase 2
- Karyopharm Expanded Access Program for SelinexorAvailableNCT07215832
- Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT07128381Phase 1/2
- Momelotinib During and After HCT in MyelofibrosisRecruitingNCT07104799Phase 1
- A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell TransplantRecruitingNCT07020533Phase 1
- A Study to Evaluate INCA035784 in Participants With Myeloproliferative NeoplasmsRecruitingNCT07008118Phase 1
- Research Platform Myelofibrosis and AnemiaRecruitingNCT06976918
- Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ CellsRecruitingNCT06896344
- A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK InhibitorsRecruitingNCT06887803Phase 1/2
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationRecruitingNCT06859424Phase 2
- Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or MyelofibrosisRecruitingNCT06781099Not applicable
- A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisRecruitingNCT06773195Phase 1/2
- Ropeginterferon Alfa 2b Plus Ruxolitinib for MyelofibrosisRecruitingNCT06770842Phase 2
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
- Haplo-HSCT for MyelofibrosisRecruitingNCT06674382Not applicable
- A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)RecruitingNCT06661915Phase 2
- Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 InhibitionRecruitingNCT06605586Phase 1/2
- MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) TrialRecruitingNCT06541249Phase 2
- Clinical Epidemiology in Contemporary Patients With Myelofibrosis.RecruitingNCT06533813
- Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisRecruitingNCT06517875Phase 2
- Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia VeraRecruitingNCT06516406
- Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to RuxolitinibRecruitingNCT06479135Phase 3
- Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingNCT06414681Early Phase 1
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- A Study of GLB-001 in Patients With Myeloid MalignanciesRecruitingNCT06378437Phase 1
- Functional and Phenotypic Characterization of Monocytes in Myeloproliferative SyndromesRecruitingNCT06361641Not applicable
- A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)RecruitingNCT06351631Phase 3
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingNCT06345495Phase 2
- A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)RecruitingNCT06343805Phase 1
- Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)RecruitingNCT06327100Phase 1/2
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
- A New Blood Score for Myelofibrosis StagingNot yet recruitingNCT06177366
- 18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.RecruitingNCT06164561
- 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis.RecruitingNCT06151119
- A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)RecruitingNCT06122831Phase 1/2
- A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With MyelofibrosisRecruitingNCT06073847
- Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative NeoplasmsRecruitingNCT06063486Phase 2
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantRecruitingNCT06059391Phase 2
- UAB 2419-CD34 Selection Using the Automated CliniMACS ProdigyRecruitingNCT06047886Phase 1
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
- Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)RecruitingNCT06022328
- A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaRecruitingNCT05980806Phase 2
- Real World Evidence of Fedratinib Effectiveness in MFRecruitingNCT05883904
- Asian Myeloproliferative Neoplasm (MPN) RegistryRecruitingNCT05882773
- A Telehealth Advance Care Planning InterventionRecruitingNCT05875805Not applicable
- Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)RecruitingNCT05835466Phase 2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Ruxolitinib in Patients With MyelofibrosisNot yet recruitingNCT05762874
- Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk MyelofibrosisRecruitingNCT05731245Phase 2
- Clonal Architecture of ASXL1-mutated MyelofibrosisRecruitingNCT05710211Not applicable
- Bomedemstat (IMG-7289) Plus Ruxolitinib for MyelofibrosisRecruitingNCT05569538Phase 2
- AlloHCT With PegINFa for MyelofibrosisRecruitingNCT05535764Phase 1
- Leading in MPNs Beyond Ruxolitinib in Combo With T-RegsRecruitingNCT05423691Phase 1
- Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and AnemiaRecruitingNCT05320198Phase 1/2
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibRecruitingNCT05280509Phase 1/2
- A Safety and Tolerability Study of JaktinibRecruitingNCT05279001Phase 1
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative NeoplasmsRecruitingNCT05198960Phase 3
- An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative NeoplasmsRecruitingNCT05123365Phase 1/2
- A Study of Elritercept Alone or Together With Ruxolitinib in Adults With MyelofibrosisRecruitingNCT05037760Phase 2
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- Ropeginterferon Alfa 2b for Early MyelofibrosisRecruitingNCT04988815Phase 2
- Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)RecruitingNCT04942080Not applicable
- Methods of T Cell Depletion Trial (MoTD)RecruitingNCT04888741Phase 2
- Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve MyelofibrosisRecruitingNCT04878003Phase 2
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.RecruitingNCT04771572Phase 1